OK
The Universal Selection Source:
Coatings Ingredients
Industry News

University of Michigan Research Team Receives Funding for Groundbreaking Polymer Coating

Published on 2007-01-31. Author : SpecialChem

BOSTON -- Allied Minds, a pre-seed investment corporation specializing in early stage university business ventures, has partnered with the University of Michigan to develop a start-up company, Biotectix LLC, which will specialize in novel bioactive electrodes and coatings specifically tailored to enhance a wide variety of medical devices.

The newly formed Biotectix LLC has signed an option agreement to exclusively license platform technology developed at the Organic Electronics and Electroactive Biomaterials Laboratory, University of Michigan, by Drs. David Martin and Sarah Richardson-Burns as well as Jeff Hendrix. "These technologies lay the groundwork for a fully integrated electrode-tissue interface," said Dr. Martin. "With such an interface, we will be able to counter the tissue injury and inflammation associated with implantation of microelectrodes and neural prosthetic devices and improve quality of life for individuals requiring such devices."

Traditional metallic biomedical device electrodes (steel, platinum, iridium, gold) are energy inefficient, hard, non-biocompatible and can cause local tissue damage and scarring. They also have limited-MRI compatibility, and often don't function for as long or as well as intended leading to more frequent battery replacement. Devices that fall into this class include pacemakers, cortical probes, cochlear implants, glucose sensors and deep brain stimulators.

Biotextix LLC has been created to address these shortcomings and has developed soft, bioactive conductive polymer electrodes and coatings for electrodes. This novel technology results in increased electrode sensitivity and charge transfer capacity conferred by polymer coatings, significantly enhancing device function and battery life. In addition, drugs can be released from the polymer coating as desired: passive, intermittent, or extended release.

"One of the most exciting aspects of the technology is its bioactive attributes. By this we mean the technology's ability to promote neural in- growth. Byproducts of this capability include improved mechanical integration and reduced immune response," said Marc Eichenberger, COO of Allied Minds. "It seems like every day we see new opportunities for these technologies. One example is to improve the interface with robotic arms being developed by the US government and others. Initially we will look to benefit key areas such as cochlear implants, deep brain stimulation and cardiac markets."

"We are very excited about this new agreement between University of Michigan and Allied Minds," said Dan Broderick, University of Michigan, Director of Office of Technology Transfer for the College of Engineering. "We see it as an effective way to augment Dr. Martin's groundbreaking research and serve as a catalyst to speed these discoveries to commercial applications for the benefit of the public. The Allied Minds team is to be commended for understanding the business case for supporting university innovation."

About Allied Minds, Inc.

Allied Minds is a pre-seed investment company creating partnerships with key universities to fund corporate spin-offs resulting from successful early stage technology research. By providing corporate development support as well as finance, Allied Minds aims to guide early stage companies to commercial success, thereby generating value for all stakeholders.

Source: Allied Minds, Inc.


Halcyon Group 3rd R&D Innovation Summit
Back to Top